Sign In
Buy RGNX
$6.69
+0.170 (+2.61%)
At Close: Jun 03, 2026
ROCKVILLE, Md. , Feb. 26, 2025 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced that it will host a conference call on Thursday, March 13, at 4:30 p.m.
REGENXBIO to Participate in Upcoming Investor Conferences
04:05pm, Tuesday, 25'th Feb 2025
ROCKVILLE, Md. , Feb. 25, 2025 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced it will participate in the following investor conferences: TD Cowen's 45th Annual Health Care Conference F
Regenxbio's Gene Therapy Outlook Dims As Rival Treatments Gain Ground, Goldman Sachs Warns
03:20pm, Tuesday, 11'th Feb 2025
Goldman Sachs downgraded Regenxbio Inc RGNX, citing gene therapy's appeal for wet AMD and diabetic retinopathy is uncertain, as most patients are elderly and newer anti-VEGF treatments offer longer-la
Wall Street Analysts Think Regenxbio (RGNX) Could Surge 333.01%: Read This Before Placing a Bet
10:56am, Monday, 10'th Feb 2025
The consensus price target hints at a 333% upside potential for Regenxbio (RGNX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate
REGENXBIO Announces Presentations of RGX-121 at the 21st Annual WORLDSymposium 2025
07:05am, Thursday, 30'th Jan 2025
ROCKVILLE, Md. , Jan. 30, 2025 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced data from its RGX-121 (clemidsogene lanparvovec) program for the treatment of mucopolysaccharidosis type II
Wall Street Analysts See a 357.36% Upside in Regenxbio (RGNX): Can the Stock Really Move This High?
10:55am, Friday, 24'th Jan 2025
The mean of analysts' price targets for Regenxbio (RGNX) points to a 357.4% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analy
Regenxbio: Wet AMD ABBV-RGX-314 Results Remain On Track For 2026
04:01am, Thursday, 16'th Jan 2025
Regenxbio's rolling BLA submission completion of RGX-121 for the treatment of patients with MPS II expected in Q1 of 2025. Partnership established with Nippon Shinyaku to develop RGX-121 and RGX-111 f
Regenxbio Inc.: Why It Is Down, And When It Will Go Up Again
03:27pm, Wednesday, 15'th Jan 2025
Regenxbio Inc. remains undervalued despite its cutting-edge AAV gene therapy technology and promising assets like RGX-314 for wet AMD and RGX-121 for MPS II. RGX-314, partnered with AbbVie, targets we
REGENXBIO and Nippon Shinyaku Announce Exclusive Partnership to Develop and Commercialize RGX-121 and RGX-111 for MPS Diseases
05:00am, Tuesday, 14'th Jan 2025
REGENXBIO to receive $110 million upfront, potential milestone payments of up to $700 million and meaningful double-digit royalties on net sales, and lead manufacturing Nippon Shinyaku to lead commerc
AbbVie and REGENXBIO Announce Updates on the ABBV-RGX-314 Clinical Program
08:31am, Monday, 13'th Jan 2025
Pivotal data evaluating the safety and efficacy of the subretinal delivery of ABBV-RGX-314 in patients with wet age-related macular degeneration (wet AMD) are expected in 2026 AbbVie and REGENXBIO wil
Apollo Global Management and Workday Set to Join S&P 500; Others to Join S&P MidCap 400 and S&P SmallCap 600
06:29pm, Friday, 06'th Dec 2024
NEW YORK , Dec. 6, 2024 /PRNewswire/ -- S&P Dow Jones Indices ("S&P DJI") will make the following changes to the S&P 500, S&P MidCap 400, and S&P SmallCap 600 indices effective prior to the open of tr
REGENXBIO INITIATES PIVOTAL PHASE OF AFFINITY DUCHENNE® TRIAL OF RGX-202 GENE THERAPY AND REPORTS POSITIVE FUNCTIONAL DATA
07:05am, Monday, 18'th Nov 2024
Alignment achieved with FDA on AFFINITY DUCHENNE® pivotal program and access to accelerated approval; BLA expected in 2026 Pivotal trial of RGX-202 is enrolling ambulatory patients aged 1 and above w
REGENXBIO to Host Webcast Discussing Pivotal Program and First Functional Data from the AFFINITY DUCHENNE® Trial of RGX-202
07:05am, Thursday, 14'th Nov 2024
- Event will feature Aravindhan Veerapandiyan, M.D., principal investigator of the AFFINITY DUCHENNE® trial and Michael Kelly, PhD, Chief Scientific Officer of CureDuchenne ROCKVILLE, Md.
REGENXBIO Inc. (RGNX) Q3 2024 Earnings Call Transcript
11:16pm, Wednesday, 06'th Nov 2024
REGENXBIO Inc. (RGNX) Q3 2024 Earnings Call Transcript
Regenxbio (RGNX) Reports Q3 Loss, Tops Revenue Estimates
07:00pm, Wednesday, 06'th Nov 2024
Regenxbio (RGNX) came out with a quarterly loss of $1.17 per share versus the Zacks Consensus Estimate of a loss of $1.16. This compares to loss of $1.41 per share a year ago.
